#ACR23 Abstr# 2488 Phase 2 RCT #SLE showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + UPA (JAK-i)) and UPA mon
Tweet Content
#ACR23 Abstr# 2488 Phase 2 RCT #SLE showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + UPA (JAK-i)) and UPA monotherapy met primary & secondary endpoints vs PBO at WK48W. No major malignancy/VTE concerns. No added superiority by adding BTK-i vs UPA alone @RheumNow https://t.co/MUN2o75gEE
Show on Archive Page
On
Display in Search Results
On
PDQ
Off